Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated December 17, 2025, reports a significant regulatory milestone. The US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused exclusively on a product approval announcement.
Material Changes and Clinical Data
The primary material change is the FDA approval of Exdensur, the first ultra-long-acting biologic with twice-yearly dosing for this indication. Key clinical data supporting the approval includes:
- Exacerbation Reduction: SWIFT-1 and SWIFT-2 trials showed a 58% and 48% reduction in the rate of annualised asthma exacerbations, respectively, compared to placebo.
- Hospitalization Reduction: A pooled analysis demonstrated a 72% reduction in clinically significant exacerbations requiring hospitalization or emergency department visits.
- Safety Profile: Depemokimab was well-tolerated with a similar rate and severity of side effects as placebo.
- Market Context: Approximately 2 million Americans live with severe asthma, with 50% experiencing frequent exacerbations. Currently, only 20% of eligible US patients receive biologic treatments.
Outlook, Management Commentary, and Risks
Management Commentary: GSK executives state that Exdensur could redefine patient care by offering sustained protection with fewer doses, potentially improving adherence and reducing health system burden. The therapy targets type 2 inflammation, the underlying cause in over 80% of severe asthma cases.
Regulatory Outlook:
- UK: Marketing authorization already received from the MHRA.
- Europe: Positive CHMP opinion received; approval decision expected in Q1 2026.
- Global: Submissions under review in China and Japan.
Pipeline: Depemokimab is in Phase III trials for chronic rhinosinusitis with nasal polyps (ANCHOR-1/2), EGPA (OCEAN), HES (DESTINY), and COPD (ENDURA-1/2).
Risks: The filing includes a standard cautionary statement that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" in GSK's 2024 Form 20-F and Q3 2025 results.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for Exdensur in the US market.
- Confirm the expected revenue contribution of Exdensur in GSK's upcoming quarterly and annual guidance.
- Monitor the Q1 2026 European approval decision and subsequent launch plans.
- Review the status of the ANCHOR, OCEAN, DESTINY, and ENDURA trials for potential expansion of the depemokimab franchise.
- Assess competitive positioning against existing biologics given the 20% current utilization rate in the US.